Summary A major form of drug resistance in tumour cells known as classical multidrug resistance (MDR) is associated with the overexpression of the mdrl gene product, the membrane protein P-glycoprotein (P-gp), which acts as an energy-dependent drug efflux pump. In this study the inheritance of P-gp expression was examined using hybrids formed after somatic cell fusion between a drug-sensitive human T-cell leukaemia cell line, CEM/CCRF, and a drug-resistant derivative, CEM/A7, which is characterised by a clonal chromosomal duplication dup(7)(ql1.23q31.2). Fourteen hybrids, chosen at random, were analysed by reverse transcriptasepolymerase chain reaction (RT-PCR) and by binding studies involving the monoclonal antibody MRK16, which recognises an external P-gp epitope. Only two hybrids were positive for both MRK16 antibody labelling and mdrl mRNA. Partial karyotypic analysis of all hybrids revealed that only the MRK16-positive hybrids contained the duplication in chromosome 7 seen in the CEM/A7 parental MDR line. Therefore, P-gp overexpression in the MRK16-positive hybrids may be linked to the inheritance of chromosome 7 from CEM/A7 and possibly associated with the chromosome 7 abnormality.
Although chemotherapy remains an important treatment modality for patients with advanced malignancy, only a small proportion are cured by currently available cytotoxic agents. The majority of malignancies are either intrinsically drug resistant or acquire resistance after initially responding to chemotherapy. A variety of factors may influence the clinical impact of any single cytotoxic agent, but drug resistance at the genetic level is thought to be one of the most important determinants in clinical outcome.
A major form of drug resistance, known as classical multidrug resistance (MDR), is characterised by cross-resistance to a variety of structurally and functionally unrelated drugs (Bradley et al., 1988) . The phenotype is associated with the overexpression of P-glycoprotein (P-gp), a high-molecular weight membrane protein of approximately 170 kDa (Croop et al., 1988) . P-gp functions as an energy-dependent drug efflux pump resulting in decreased intracellular accumulation of cytotoxic agents in resistant cells. Consequently, the regulation of P-gp expression in resistant tumour cells is the focus of many studies.
The human P-gp molecule is encoded by the mdrl gene, which has been localised to chromosome 7 (Fojo, et al., 1986) . Chromosome 7 abnormalities have been previously described in MDR cells containing mdrl gene amplification and overexpressing P-gp (Slovak et al., 1987; Nieuwint et al., 1992) . In these cells, P-gp overexpression was commonly accompanied by various abnormalities of the long arm of chromosome 7, usually with breakpoints close to the mdrl locus, 7q21.1 (Nieuwint et al., 1992) . However, it is currently unknown whether the structural rearrangements of chromosome 7 observed in MDR cell lines actually lead to alterations in the expression of P-gp.
It has been established that marker chromosomes can be inherited by hybrid cells resulting from somatic cell fusions (Palyi et al., 1994) . Therefore, the clonal chromosomal duplication of the region 7ql 1.23q31.2 that characterises the MDR variant of the CEM/CCRF drug-sensitive cell line, CEM/A7, (Zalcberg et al., 1994) provides a marker for the investigation of the inheritance of chromosome 7 and P-gp overexpression.
In the past, studies employing somatic cell fusion techniques have been used to determine the dominance of the classical MDR phenotype. Difficulties in the interpretation of the results relate to the use of cells with complex phenotypes involving more than one mode of drug resistance and the use of a 'drug-sensitive' parental line, which in fact expressed low levels of P-gp (Eijdems et al., 1992) . Additionally, previous findings suggesting that the classical MDR phenotype is dominant, or at least co-dominantly expressed, have also been complicated by the use of phenotypically unstable resistant parental lines in which amplified copies of the mdrl gene resided on unstable chromosomal elements (Akiyama et al., 1985) . In such studies, expression of mdrl genes harboured on circular DNAs are not necessarily confined to the regulatory constraints of cis-acting factors on chromosome 7.
In the present study, although the issue of the dominance of mdrl gene expression is not addressed, the expression of P-gp in hybrid cell lines was examined in a model designed to overcome the issues that confounded previous somatic cell fusion experiments. The sensitive parental line was truly P-gp negative, as determined by the polymerase chain reaction (PCR) while the resistant parental line overexpressed P-gp without the concomitant amplification of the mdrl gene (Zalcberg et al., 1994) seen in most classical MDR cell lines used previously. Karyotypic analyses of chromosome 7 were performed in the hybrid lines and cytotoxic agents were not added to the post fusion medium thus avoiding any selective pressure for expression of the MDR phenotype.
Materials and methods

Cell lines and culture conditions
The MDR variant of the CEM/CCRF line, CEM/A7 (Zalcberg et al., 1994) was used as the drug-resistant parental line for the fusion experiments and was grown in 0.07 ig ml-' doxorubicin (David Bull Laboratories, Melbourne, Australia). Cells were grown in RPMI 1640 (Gibco Labs) supplemented with 10% fetal calf serum (FCS, Flow Labs, Australia) and 0.8 mM glutamine at 37TC, in a humidified chamber in an atmosphere of 5% carbon dioxide in air.
Correspondence: JR Zalcberg, Director, Medical Oncology, Austin The cell line, CEM/CCRF (Foley et al., 1965) represented the drug-sensitive parental line into which selective markers were introduced. CEM/CCRF cells were cultured in increasing concentrations of the purine antagonist, 2-amino-6-mercaptopurine (6-thioguanine, Sigma Pharmaceuticals) and finally maintained in medium containing 20 fig ml-' 6- thioguanine. The resulting cell line was unable to grow in HAT medium, indicating a deficiency in the purine nucleotide salvage pathway enzyme hypoxanthine-guanine phosphoribosyl transferase (HGPRT) . The resulting HGPRT -/ CCRF cells were stably transfected with the bacterial aminoglycoside phosphotransferase 3' (II) gene which confers resistance to the antibiotic neomycin and its derivatives (Hanchett et al., 1992) . All cells were mycoplasma-free when tested by the Gen-Probe mycoplasma assay (GEN-PROBE, San Diego, CA, USA).
Transfection of the mutant drug-sensitive parent HGPRT -/CCRF cells, in logarithmic growth phase, were washed three times in cold, serum-free RPMI-1640 and adjusted to a concentration of 2 x I07 cells ml-before electroporation. Cells (500 !ld) were mixed with 20 pg of pSV 2-neo plasmid DNA (Southern and Berg, 1982) and incubated on ice for 5 min before electroporation at 270V and 960 lF using a Gene Pulser (Bio-Rad Laboratories, Richmond, CA, USA). The cells were then left on ice for 10min and resuspended in 6ml of complete medium. The suspension was centrifuged at 800 r.p.m. for 1.5 min to remove debris and the pellet was resuspended in 10ml of complete medium. Cells were grown in non-selective medium for 48 h, after which 400 jig ml-1 of the neomycin analogue geneticin sulphate (G418, Gibco Laboratories, Grand Island, NY, USA) and 20ligml-' 6-thioguanine were added to the medium.
Somatic cellfusions
Hybrids of drug-sensitive and -resistant cells were generated by mixing HGPRT-/NeoR/CCRF (HNCCRF) sensitive cells with CEM/A7 resistant cells, in logarithmic growth phase, at a ratio of 1:5 yielding a total of 2 x 107 cells. Cells were washed three times in serum-free RPMI-1640 to remove FCS from the culture medium. Polyethylene glycol [PEG 4000, 0.8 ml, 50% w/v in phosphate-buffered saline (PBS), Boehringer Mannheim] was added dropwise over 1 min to a dispersed pellet and the suspension was incubated at 37°C for 3 min. To dilute out the PEG, 2 ml of serum-free RPMI 1640 was added over 1 min with gentle mixing. Serum-free medium (8 ml) was then added and the cell clumps were spun down at 500 r.p.m. for 3 min and resuspended in 40 ml of complete medium.
The cells were plated out into 96-well plates (Flow Labs) at a density of 5 x 104 cells per well and were incubated for 24 h in non-selective medium at 37°C. Selective medium (100 dl of 1 x HAT: o0-6 M hypoxanthine, 4 x l0-5 M aminopterin, 1.6 x l0-5 M thymine from ICN Flow, California, USA; 400 ytg ml-' G418) was added to each well. Medium was replaced with fresh selective medium every 3 days. Resultant hybrids were expanded into 24-well plates and from there into 25 cm2 tissue culture flasks (Flow Labs).
Growth assays
Growth assays for the CEM/CCRF, HNCCRF and CEM/ A7 lines were performed on actively growing cells in varying concentrations of either doxorubicin or vinblastine (David Bull Laboratories) in triplicate. The assays were performed as previously described (Hu et al., 1990 ) with cells in logarithmic growth phase at a density of 5 x 104 cells ml-' seeded into 24-well plates. After 3 days, cell counts were determined using a Coulter Counter (Model DN, Coulter Electronics, Luton, England). The IC50 value (the dose that inhibits cell growth by 50% relative to untreated controls) was determined for each cell line for both drugs. Additionally, the growth of cells in either HAT medium or varying concentrations of G418 was assessed. Cells were plated out at a density of 103 cells ml-and cell numbers determined following 7 and 14 days' incubation in HAT medium or 16 days' incubation in G418 at 37°C.
Similarly, drug resistance profiles for the parental CEM/ CCRF, HNCCRF a'nd CEM/A7 lines and four hybrid cell samples were determined using actively growing cells in varying concentrations of the cytotoxic agent epirubicin (David Bull Laboratories). Experiments were performed in triplicate as described above.
MRK16 screening Cellular expression of P-gp was determined using a FACScan flow cytometer (Becton Dickinson, California, USA). The assay involved the use of a monoclonal antibody, MRK16 (gift from Dr Tsuruo, Division of Experimental Chemotherapy, Japanese Foundation for Cancer Research), in a method previously described (Wall et al., 1993) with minor modifications. Briefly, exponentially growing cells (106 cells ml -') were pelleted. The pellet was dispersed and to one tube 0.37 ,tg of the monoclonal antibody MRK16 was added.
To the other duplicate 1 tsg of the non-specific murine monoclonal antibody, IgG 2a control (Becton Dickinson) was added to act as a control. The tubes were then incubated at room temperature for 20 min. Each sample was washed twice in complete medium and 0.5 jg of a fluoresceinconjugated goat anti-mouse antibody (Becton Dickinson) was added. Samples were then incubated at room temperature for 20 min in the dark. Finally the cells were washed three times in complete medium and analysed in the flow cytometer.
RNA extraction and preparation of cDNA RNA was extracted from both the parental cell lines and randomly selected hybrid cells using the guanidinium thiocyanate phenol chloroform method described by Chomczynski and Sacchi (1987) Cytogenetic analysis Chromosome preparations were obtained using standard procedures (Webber and Garson, 1983) and G-banded chromosomes were assembled and described according to the International System of Human Cytogenetic Nomenclature recommendations (ISCN, 1991) . Only chromosome 7 of each hybrid was examined in detail since the karyotype from both parental cells has been previously reported (Zalcberg et al., 1994) .
Results
Isolation and characterisation ofparental cell lines Two selective markers were introduced into the sensitive, parental cell line, CEM/CCRF to produce the HNCCRF cell line for use in the fusion experiments. Initially, CEM/CCRF cells were cultured in increasing concentrations of the purine antagonist 6-thioguanine to select for cells deficient in the purine nucleotide salvage pathway enzyme, HGPRT. These cells were maintained in 20 yg ml-' 6-thioguanine. Subsequently these HGPRT-mutant cells were electroporated with the pSVneo plasmid and cultured in medium also containing G418 (a neomycin analogue) to select for the HGPRT-and G418-resistant double mutant referred to as HNCCRF. Although a deletion or mutation in the HGPRT gene was not specifically demonstrated, the fact that this cell line was completely inhibited in HAT medium, suggests the HGPRT gene product was non-functional.
Before cell fusion, the drug resistance profile for the two parental cell lines was determined in order to see whether the creation of the double mutant, HNCCRF, had altered the drug resistance profile or induced expression of P-gp. The HNCCRF mutant remained sensitive to doxorubicin and vinblastine relative to the resistant cell line, CEM/A7. There was a minor increase in doxorubicin resistance and a decrease in vinblastine resistance relative to CEM/CCRF cells (Table I) .
To confirm that HNCCRF was truly negative for P-gp expression, MRK16 binding analysis by flow cytometry was conducted. As demonstrated in Table II , P-gp expression was observed only in the CEM/A7 cell line. Both CEM/CCRF and HNCCRF failed to express P-gp. These results were confirmed by reverse transcriptase (RT)-PCR analysis of RNA extracted from these cell lines. Although all cells contained the mdrl gene, no mdrl mRNA was detected in the CEM/CCRF or HNCCRF lines (Table II) Of the 14 hybrids analysed for MRK16 binding, only two were positive (ICIO, 2GI0). Relative to that observed in the CEM/A7 parent (100%), the binding of MRK16 in these hybrids was 86% and 75% respectively (Table II) . The remainder of the hybrids were all negative for MRK16 binding, indicating no P-gp expression. The hybrids were all stable with respect to viability and MRK16 status.
RNA was extracted from 11 of the hybrids and was analysed by RT-PCR (Figure 1 ). The only hybrids to yield a PCR product of the expected size were ICIO and 2GI0, the same hybrids that gave a positive MRK16 labelling result. Primers to the histone 3.3 gene provided an internal control ensuring that RNA was present in each sample. Genomic DNA extracted from the same hybrids was also analysed by PCR (data not shown) using primers that anneal to the promoter region of the mdrl gene. All hybrids were found to be positive for mdrl genomic DNA suggesting that all hybrids had retained the mdrl gene.
Drug resistance profile of the hybrid cells Resistance to epirubicin was determined in the two P-gppositive hybrids, lCIO and 2GI0, two hybrid cell samples negative for the expression of P-gp, 2H6 and 4G9, as well as r-1 171 Table II MRK16 the parental cell lines CEM/CCRF, HNCCRF and CEM/A7 (Figure 2 ). The two hybrid cells that expressed both mdrl mRNA and P-gp also exhibited a resistance to the cytotoxic drug, epirubicin, similar to the MDR cell line CEM/A7. In contrast, the two drug-sensitive cell lines, CEM/CCRF and HNCCRF and the two P-gp-negative hybrids, 2H6 and 4G9, were sensitive to epirubicin.
Cytogenetic analysis of hybrids
The parental cell lines used in this study have been previously karyotyped (Zalcberg et al., 1994) . Both contain mainly neartetraploid metaphases with the modal number of chromosomes ranging from 89 to 102. Structural changes in both cell lines are consistent as the CEM/A7 line was originally derived from the CEM/CCRF line. The main difference between the parental cell lines is that the CEM/A7 cell line contains a duplication in chromosome 7, dup(7)(ql 1.23q31.2). This duplication appears to include the mdrl gene locus which is located at 7q21.1 (Trent and Callen, 1991) . Cytogenetic analysis of the hybrids revealed that only the MRK16-positive hybrids 2G10 and ICIO contained abnormalities of chromosome 7. The specific abnormality was identified to be the same as that seen in the CEM/A7 cell line, a duplication involving the region qI 1.23q31.2. All other hybrids contained only normal copies of chromosome 7 as observed in the drug-sensitive parental line, CEM/CCRF. Figure 3 shows a normal chromosome 7 as well as the abnormal chromosome 7 in the hybrid lCIO.
Discussion
In a previous report, we described the derivation of the drug-resistant CEM/A7 cell line in which we identified an abnormality on chromosome 7 (Zalcberg et al., 1994) . This chromosomal abnormality provided us with a unique marker for studying the inheritance of chromosome 7 and drug resistance in hybrids obtained from somatic cell fusion experiments. A double mutant from the drug-sensitive human T-cell leukaemia cell line CEM/CCRF was created for use in fusion experiments. The CEM/CCRF parental cell line was selected because it lacked P-gp expression as determined by MRK16 labelling and RT-PCR analysis, thus providing a truly P-gpnegative, drug-sensitive parent. In contrast, the drug-resistant CEM/A7 cell line was strongly positive for P-gp as determined by both of these assays. The double mutant HNC-CRF, was deficient in the HGPRT enzyme and carried the gene for neomycin resistance. Examination of the growth assays performed in the presence of increasing concentrations of doxorubicin and vinblastine clearly showed that HNC-CRF essentially maintained its sensitivity to these drugs, having an IC50 value similar or very close to that of the CEM/CCRF parental cell line from which it was derived (Table II) In contrast, the CEM/A7 line demonstrated resistance to both drugs, especially to doxorubicin, the drug against which it was primarily selected.
Growth of the HNCCRF and CEM/A7 cell lines was abolished in selective medium containing both HAT and G418, allowing the selection of hybrids that would have had to inherit the HGPRT enzyme from the CEM/A7 cell line and neomycin resistance from the HNCCRF cell line. This selection procedure was relatively slow, requiring about 10 weeks for most hybrids to be numerous enough for characterisation and ploidy analysis 5 weeks after fusion indicated that chromosomal segregation had already taken place (data not shown). However, compared with the cytotoxic drugs used by other groups (Ling and Baker, 1978; Eijdems et al., 1992; McLean et al., 1993) , this selection procedure was less likely to influence the P-gp status of resulting hybrids.
Since chromosomal segregation had occurred in the hybrids, it was possible that the absence of P-gp expression in the MRK16-negative hybrids was due to the loss of the mdrl gene. However, PCR analysis of genomic DNA (data not shown) confirmed the presence of the mdrl gene in all hybrids, including those that failed to demonstrate P-gp expression. In contrast, RT-PCR analysis carried out on the same cells indicated that mdrl mRNA was only detectable in the two MRK16-positive hybrids, ICIO and 2G10 (Figure 1 ).
I
The MRK16 binding results (Table lI) indicate higher P-gp positivity in the ClIO hybrid sample as compared with that of 2G10. This is supported by the functional analysis of drug resistance to the cytotoxic agent epirubicin (Figure 2 ) showing a higher IC,-, value for ICI0 than for 2G10 (600 ngmVm and 430 ng ml-respectively.) suggesting that the hybrid ICIO was more drug resistant than 2GI1. at least to epirubicin. In contrast. the RT-PCR analysis (Figure 1 ) suzgested that the expression of midrl mRNA was in fact higher in the 2G10 hvbrid. However. the PCR technique used in this study was not quantitative and therefore the intensity of the bands is not indicative of the level of mRNA expression. Also. previous investigations have shown that it is possible for P-gp to be overexpressed wvithout a simultaneous increase in mdrl mRNA levels (Zhao et al.. 1994) . Hence the RT-PCR anal-sis merely indicates the presence or absence of rmdrl mRNA.
Although the post fusion selection procedure was lengthy. preliminary characterisation of another group of hybrids during this time revealed strong M RK 16 positivity. However. these hybrids were not viable at 10 weeks (data not shown). Similarly, in another group of hy%brids that contained a combination of both MRK 16-positive and -negative cells. only the negative cells were present 10 weeks after fusion. This apparent grow-th advantage of MRK16-negative cells and unstable MDR phenotype in the absence of selective pressure is not a new phenomenon. Ling and Baker (1978) added graded concentrations of colchicine to their post fusion selection medium but also noted that h-brids lost their resistance when cultured in the absence of colchicine. Akivama et al. (1985) tested hy-brids grown in the absence of cv-totoxic agents for functional resistance at 9 and 13 weeks after fusion and demonstrated a loss of resistance. They suggested that unstable. extrachromosomal genetic elements in the parental cells may be responsible for this observation. However. in the present study the drug-resistant CEM A7 cell line has a stable phenotype. When cultured in the absence of cVtotoxic agents for more than 12 months. the cells still overexpressed P-gp. althouah at a reduced level (Zalcberg et al.. 1994) .
CN-togenetic analy-sis of chromosome 7 in all 14 hy-brid cell lines revealed the same duplication. dup(7Nqll.23q31.2) in just two hvbrids. 2GI0 and lCIO. This abnormality appeared to involve the rndrl locus at 7q21.1. The abnormality was identical to that observed in the drug-resistant CEM A7 parental cell line (Zalcberg et al.. 1994 ). All other hy-brids contained only normal copies of chromosome 7 as seen in the drug-sensitive parental cell line. CEM CCRF. The two hvbrids with the dup(7q) kar-otypic abnormality were the onlv two hy-brids to express P-gp and rnzdrl mRNA based on MRK16 labelling and RT-PCR assays respectively. As these two hybrids and CEM A7 overexpress P-gp and contain the same duplication in chromosome 7. it would appear that P-gp overexpression may be linked to the inheritance of the abnormal chromosome 7 from the drug-resistant parental cell line. CEM A7. While the inheritance of other chromosomal factors from the CEM A7 line cannot be excluded as the cause for increased expression of P-ep. we believe the data sugaest that the common karyotypic abnormalities in chromosome 7 may be the causal factor.
Although the duplicated region observed in the CEM A7 cell line has not been characterised. it provides a marker w-ith which to study the inheritance of chromosome 7. It is unknown whether the association shown in our data betu-een the overexpression of P-gp and the inheritance of chromosome 7 from a resistant cell line is causally linked. however we are currently attempting to map the duplication and site of insertion of this duplication in the drug-resistant CEM A7 cell line to further our know-ledge of this chromosomal abnormality.
